{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:55:57Z","timestamp":1793436957328,"version":"4.5.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>In this review, we outline the usage and formulations of gonadotropin-releasing hormone analogs (GnRHas) in central precocious puberty (CPP), short stature, and gender diverse individuals, as well as adverse effects, long-term outcomes, and monitoring of therapy. There is a particular focus on citing references published within the last 24\u200amonths.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Long-acting formulations of GnRHa now include Federal Drug Administration approval for subcutaneous injections. Significant adverse events continue to be rarely reported; extremely rare events include arterial hypertension and pseudotumor cerebri. There continue to be no significant long-term consequences including the impact upon body mass index and bone mineral density, which appear to be transient. GnRHas have been used in differences of sexual development (DSD) and increasingly in the treatment of adolescent transgender individuals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>GnRHas remain as the only fully efficacious therapy for CPP and effectively suppress pubertal hormones in other situations. The use of GnRHa therapy in gender incongruent individuals has proven beneficial and has become a standard of care, whereas use in those with DSDs should still be considered experimental.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Video abstract<\/jats:title>\n            <jats:p>\n                                 http:\/\/links.lww.com\/MOP\/A62.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001026","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T03:00:07Z","timestamp":1621306807000},"page":"442-448","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Use of gonadotropin-releasing hormone analogs in children"],"prefix":"10.1097","volume":"33","author":[{"given":"Natalie G.","family":"Allen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanthi Bangalore","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000501336","article-title":"Use of gonadotropin-releasing hormone analogs in children: update by an International Consortium","volume":"91","author":"Bangalore Krishna","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jpeds.2013.05.033","article-title":"A single histrelin implant is effective for 2\u200ayears for treatment of central precocious puberty","volume":"163","author":"Lewis","year":"2013","journal-title":"J Pediatr"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00003495-198835010-00004","article-title":"GnRH agonists and antagonists. Current clinical status","volume":"35","author":"Filicori","year":"1988","journal-title":"Drugs"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1552-6909.1994.tb01922.x","article-title":"Uses of GnRH agonists","volume":"23","author":"Garner","year":"1994","journal-title":"J Obstet Gynecol Neonatal Nurs"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1515\/jpem-2019-0414","article-title":"Utility and duration of leuprolide stimulation testing in children","volume":"33","author":"Nijjar","year":"2020","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1080\/09513590.2020.1718642","article-title":"Inhibin B as a screening tool for early detection and treatment monitoring of central precocious puberty","volume":"36","author":"Jeong","year":"2020","journal-title":"Gynecol Endocrinol"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.3346\/jkms.2018.33.e329","article-title":"Prevalence of pathological brain lesions in girls with central precocious puberty: possible overestimation?","volume":"33","author":"Yoon","year":"2018","journal-title":"J Korean Med Sci"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13633-016-0027-5","article-title":"Do 6-8\u200ayear old girls with central precocious puberty need routine brain imaging?","volume":"2016","author":"Kaplowitz","year":"2016","journal-title":"Int J Pediatr Endocrinol"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fphar.2019.00104","article-title":"Pelvic ultrasound in diagnosing and evaluating the efficacy of gonadotropin-releasing hormone agonist therapy in girls with idiopathic central precocious puberty","volume":"10","author":"Yu","year":"2019","journal-title":"Front Pharmacol"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1210\/jc.2019-00233","article-title":"The beneficial effect of combined GH\/GnRHa therapy in increasing adult height outcome in children with ISS","volume":"104","author":"Lazar","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1530\/EC-18-0137","article-title":"Growth hormone in combination with leuprorelin in pubertal children with idiopathic short stature","volume":"7","author":"Benabbad","year":"2018","journal-title":"Endocr Connect"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1159\/000499929","article-title":"The effect of gonadotropin-releasing hormone analogue on final adult height in children with idiopathic short stature","volume":"28","author":"Khawaja","year":"2019","journal-title":"Med Princ Pract"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1210\/jc.2016-1317","article-title":"Puberty and pubertal growth in GH-treated SGA children: effects of 2 years of GnRHa versus no GnRHa","volume":"101","author":"van der Steen","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1111\/j.1743-6109.2010.01943.x","article-title":"Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study","volume":"8","author":"de Vries","year":"2011","journal-title":"J Sex Med"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2213-8587(17)30099-2","article-title":"Puberty suppression in transgender children and adolescents","volume":"5","author":"Mahfouda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an endocrine society clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"R18-20250730","first-page":"101237","article-title":"Hormonal suppression of mini-puberty in a neonate with mosaic 45X\/46XY disorder of sexual development","volume":"32","author":"Kaefer","year":"2020","journal-title":"Urol Case Rep"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1179558119870163","article-title":"Fertility preservation using GnRH agonists: rationale, possible mechanisms, and explanation of controversy","volume":"13","author":"Blumenfeld","year":"2019","journal-title":"Clin Med Insights Reprod Health"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"e3660","DOI":"10.1210\/clinem\/dgaa479","article-title":"Phase 3 trial of a small-volume subcutaneous 6-month duration leuprolide acetate treatment for central precocious puberty","volume":"105","author":"Klein","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R21-20250730","first-page":"345","article-title":"Long-term effects and significant Adverse Drug Reactions (ADRs) associated with the use of Gonadotropin-Releasing Hormone analogs (GnRHa) for central precocious puberty: a brief review of literature","volume":"90","author":"De Sanctis","year":"2019","journal-title":"Acta Biomed"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13633-020-00092-4","article-title":"Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty","volume":"2020","author":"Omar","year":"2020","journal-title":"Int J Pediatr Endocrinol"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4274\/jcrpe.2212","article-title":"Pseudotumour cerebri presentation in a child under the gonadotropin-releasing hormone agonist treatment","volume":"8","author":"G\u00fcl","year":"2016","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1515\/jpem-2018-0210","article-title":"Does the risk of arterial hypertension increase in the course of triptorelin treatment?","volume":"33","author":"Palma","year":"2020","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fped.2019.00074","article-title":"Transient arterial hypertension induced by gonadotropin-releasing hormone agonist treatment for central precocious puberty","volume":"7","author":"Sifaki","year":"2019","journal-title":"Front Pediatr"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1089\/lgbt.2020.0026","article-title":"Blood pressure dynamics after pubertal suppression with gonadotropin-releasing hormone analogs followed by testosterone treatment in transgender male adolescents: A Pilot Study","volume":"7","author":"Perl","year":"2020","journal-title":"LGBT Health"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1159\/000504446","article-title":"Outcomes of patients with central precocious puberty due to loss-of-function mutations in the MKRN3 gene after treatment with gonadotropin-releasing hormone analog","volume":"110","author":"Ramos","year":"2020","journal-title":"Neuroendocrinology"},{"key":"R28-20250730","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1515\/jpem-2020-0386","article-title":"Effectiveness of basal LH in monitoring central precocious puberty treatment in girls","volume":"34","author":"Calcaterra","year":"2021","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R29-20250730","first-page":"121","article-title":"Diagnostic value of urinary luteinizing hormone levels in the monitoring of precocious puberty treatment","volume":"64","author":"Y\u00fcce","year":"2020","journal-title":"Arch Endocrinol Metab"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"e20171703","DOI":"10.1542\/peds.2017-1703","article-title":"Age at menarche, depression, and antisocial behavior in adulthood","volume":"141","author":"Mendle","year":"2018","journal-title":"Pediatrics"},{"key":"R31-20250730","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1515\/jpem-2019-0108","article-title":"Psychological effects of gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty","volume":"32","author":"Yu","year":"2019","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R32-20250730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3345\/kjp.2015.58.1.1","article-title":"Long-term effects of gonadotropin-releasing hormone analogs in girls with central precocious puberty","volume":"58","author":"Kim","year":"2015","journal-title":"Korean J Pediatr"},{"key":"R33-20250730","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1515\/jpem-2018-0482","article-title":"The alteration of IGF-1 levels and relationship between IGF-1 levels and growth velocity during GnRH analogue therapy","volume":"33","author":"Muratoglu Sahin","year":"2020","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R34-20250730","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1210\/clinem\/dgz027","article-title":"Long-term outcomes of treatments for central precocious puberty or early and fast puberty in Chinese girls","volume":"105","author":"Fu","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"24","DOI":"10.6065\/apem.2020.25.1.24","article-title":"Relationship between final adult height and birth weight after gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty","volume":"25","author":"Cho","year":"2020","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"R36-20250730","doi-asserted-by":"crossref","first-page":"e0243212","DOI":"10.1371\/journal.pone.0243212","article-title":"Long-term outcomes after gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty","volume":"15","author":"Shim","year":"2020","journal-title":"PLoS One"},{"key":"R37-20250730","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1515\/jpem-2019-0214","article-title":"Long-term effects of GnRH agonist treatment on body mass index in girls with idiopathic central precocious puberty","volume":"33","author":"Vuralli","year":"2020","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R38-20250730","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1515\/jpem-2019-0136","article-title":"Near final adult height, and body mass index in overweight\/obese and normal-weight children with idiopathic central precocious puberty and treated with gonadotropin-releasing hormone analogs","volume":"32","author":"Sinthuprasith","year":"2019","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R39-20250730","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1515\/jpem-2020-0019","article-title":"Menstrual cycle, reproductive function, body mass index, and metabolic profiles of women with former central precocious puberty: 10-20-year longitudinal cohort study in southern Thailand","volume":"33","author":"Satitpatanapan","year":"2020","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R40-20250730","doi-asserted-by":"crossref","first-page":"169","DOI":"10.6065\/apem.1938176.088","article-title":"Changes in body mass index in boys with central precocious puberty over 2\u200ayears of gonadotropin-releasing hormone agonist therapy","volume":"25","author":"Lim","year":"2020","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"R41-20250730","doi-asserted-by":"crossref","first-page":"53","DOI":"10.21037\/apm.2020.01.04","article-title":"Effect of gonadotropin-releasing hormone analog on ovarian reserve in children with central precocious puberty","volume":"9","author":"Tao","year":"2020","journal-title":"Ann Palliat Med"},{"key":"R42-20250730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgaa287","article-title":"Longitudinal study on metabolic health in adults sga during 5 years after GH with or without 2 years of GnRHa treatment","volume":"105","author":"Goedegebuure","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R43-20250730","first-page":"298","article-title":"Gonadotropin-releasing hormone (GnRHa) therapy for central precocious puberty (CPP): review of nuances in assessment of height, hormonal suppression, psychosocial issues, and weight gain, with patient examples","volume":"15","author":"Klein","year":"2018","journal-title":"Pediatr Endocrinol Rev"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:10:09Z","timestamp":1753899009000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001026","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,17]]}}}